330 related articles for article (PubMed ID: 36172735)
1. [Research Advances of Immunotherapy of Exosome PD-L1
in Non-small Cell Lung Cancer].
Wang N; Song X
Zhongguo Fei Ai Za Zhi; 2022 Sep; 25(9):689-695. PubMed ID: 36172735
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
Front Immunol; 2021; 12():799455. PubMed ID: 35069581
[TBL] [Abstract][Full Text] [Related]
3. Tumor-derived exosomal PD-L1: a new perspective in PD-1/PD-L1 therapy for lung cancer.
Wu Y; Fu H; Hao J; Yang Z; Qiao X; Li Y; Zhao R; Lin T; Wang Y; Wang M
Front Immunol; 2024; 15():1342728. PubMed ID: 38562933
[TBL] [Abstract][Full Text] [Related]
4. Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer.
Cheng Y; Li H; Zhang L; Liu JJ; Yang CL; Zhang S
Chin Med J (Engl); 2021 Jun; 134(15):1780-1788. PubMed ID: 34133356
[TBL] [Abstract][Full Text] [Related]
5. [Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer].
;
Zhongguo Fei Ai Za Zhi; 2021 Nov; 24(11):743-752. PubMed ID: 34802204
[TBL] [Abstract][Full Text] [Related]
6. Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer.
Meyers DE; Bryan PM; Banerji S; Morris DG
Curr Oncol; 2018 Aug; 25(4):e324-e334. PubMed ID: 30111979
[TBL] [Abstract][Full Text] [Related]
7. Exosomal PD-L1 in cancer and other fields: recent advances and perspectives.
Lu MM; Yang Y
Front Immunol; 2024; 15():1395332. PubMed ID: 38726017
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer.
Zhou K; Li S; Zhao Y; Cheng K
Front Immunol; 2023; 14():1127071. PubMed ID: 36845142
[TBL] [Abstract][Full Text] [Related]
9. Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer.
Li Y; Sharma A; Schmidt-Wolf IGH
Mol Cancer; 2024 Apr; 23(1):80. PubMed ID: 38659003
[TBL] [Abstract][Full Text] [Related]
10. Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review.
Galle P; Finn RS; Mitchell CR; Ndirangu K; Ramji Z; Redhead GS; Pinato DJ
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38238030
[TBL] [Abstract][Full Text] [Related]
11. Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee.
Mino-Kenudson M; Schalper K; Cooper W; Dacic S; Hirsch FR; Jain D; Lopez-Rios F; Tsao MS; Yatabe Y; Beasley MB; Yu H; Sholl LM; Brambilla E; Chou TY; Connolly C; Wistuba I; Kerr KM; Lantuejoul S;
J Thorac Oncol; 2022 Dec; 17(12):1335-1354. PubMed ID: 36184066
[TBL] [Abstract][Full Text] [Related]
12. Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance.
Rodriguez BL; Chen L; Li Y; Miao S; Peng DH; Fradette JJ; Diao L; Konen JM; Alvarez FRR; Solis LM; Yi X; Padhye A; Gibson LA; Ochieng JK; Zhou X; Wang J; Gibbons DL
Front Immunol; 2023; 14():1161869. PubMed ID: 37449205
[TBL] [Abstract][Full Text] [Related]
13. Bifunctional molecular probe targeting tumor PD-L1 enhances anti-tumor efficacy by promoting ferroptosis in lung cancer mouse model.
Shao C; Yan X; Pang S; Nian D; Ren L; Li H; Sun J
Int Immunopharmacol; 2024 Mar; 130():111781. PubMed ID: 38442580
[TBL] [Abstract][Full Text] [Related]
14. Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory.
Poggio M; Hu T; Pai CC; Chu B; Belair CD; Chang A; Montabana E; Lang UE; Fu Q; Fong L; Blelloch R
Cell; 2019 Apr; 177(2):414-427.e13. PubMed ID: 30951669
[TBL] [Abstract][Full Text] [Related]
15. Optimization of cancer immunotherapy on the basis of programmed death ligand-1 distribution and function.
Zou W; Luo X; Gao M; Yu C; Wan X; Yu S; Wu Y; Wang A; Fenical W; Wei Z; Zhao Y; Lu Y
Br J Pharmacol; 2024 Jan; 181(2):257-272. PubMed ID: 36775813
[TBL] [Abstract][Full Text] [Related]
16. Exosomal immune checkpoint protein (PD-L1): Hidden player in PD-1/PD-L1 blockade immunotherapy resistance in oral cancer.
Rajanathadurai J; Sindya J; Madar IH; Perumal E
Oral Oncol; 2024 Apr; 151():106748. PubMed ID: 38471246
[No Abstract] [Full Text] [Related]
17. PD-1 regulation in immune homeostasis and immunotherapy.
Gao M; Shi J; Xiao X; Yao Y; Chen X; Wang B; Zhang J
Cancer Lett; 2024 Apr; 588():216726. PubMed ID: 38401888
[TBL] [Abstract][Full Text] [Related]
18. Generation, secretion and degradation of cancer immunotherapy target PD-L1.
Shen DD; Bi YP; Pang JR; Zhao LJ; Zhao LF; Gao Y; Wang B; Liu HM; Liu Y; Wang N; Zheng YC; Liu HM
Cell Mol Life Sci; 2022 Jul; 79(8):413. PubMed ID: 35819633
[TBL] [Abstract][Full Text] [Related]
19. Regulation of Tumor Dendritic Cells by Programmed Cell Death 1 Pathways.
Knutson KL
J Immunol; 2024 May; 212(9):1397-1405. PubMed ID: 38621195
[TBL] [Abstract][Full Text] [Related]
20. Interplay between inflammasomes and PD-1/PD-L1 and their implications in cancer immunotherapy.
Jiao Z; Zhang J
Carcinogenesis; 2023 Dec; 44(12):795-808. PubMed ID: 37796835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
